CSL limited CEO: R&D spending trumps deal-making over Long term

At a time when many large pharma companies are slashing costs and cutting deals, blood plasma therapeutics specialist CSL Limited is increasing R&D spending to build value, says the company's CEO Paul Perreault. Perreault says the company's R&D mode